na začátek1.
Ackenheil, M.: The mechanism of action of antidepressants revised. J.
Neural Transm. 1990; 32 [Suppl]: 29-37.
2.
Akiyoshi, J., Hough, C., Chuang, D.-M.: Paradoxial increase of
5-hydroxytryptamine2 receptors and 5-hydroxytryptamine2
receptor mRNA in cerebral granule cells after persistent 5-hydroxytryptamine2
receptor stimulation. Mol. Pharmacol. 1993; 43: 349-355.
3.
Andersen, P.H., Klysner, R., Geisler, A.: Fluoride-stimulated adenylate
cyclase activity in rat brain following chronic treatment with psychotropic
drugs. Neuropharmacol. 1984; 23 (4): 445-447.
4.
Ansseau, M.: The paradox of neurochemical and clinical properties of
serotonergic antidepressants. In: S.Z. Langer, N. Brunello, G. Racagni, J.
Mendlewicz, eds. Critical Issues in the Treatment of Affective Disorders. Int.
Acad. Biomed. Drug Res., vol. 9. Basel: Karger, 1994; 127-135.
5.
Arana, G.W., Baldessarini, R.J., Ornsteen, M.: The dexamethasone
suppression test for diagnosis and prognosis in psychiatry. Arch. Gen.
Psychiatry 1985; 42: 1193-1204.
6.
Arora, R.C., Meltzer, H.Y.: Increased serotonin2 (5-HT2)
receptor binding as measured by 3H-lysergic acid diethylamide (3H-LSD)
in the blood platelets of depressed patients. Life Sci. 1989; 44: 725-734.
7.
Artigas, F.: 5-HT and antidepressants: new views from microdialysis
studies. TiPS 1993; 14: 262.
8.
Asakura, M., Tsukamoto, T., Kubota, H., Imafuku, J., Ino, M., Nishizaki,
J., Sato, A., Shinbo, K., Hasegawa, K.: Role of serotonin in the regulation of b-adrenoceptors
by antidepressants. Eur. J. Pharmacol. 1987; 141: 95-100.
9.
Åsberg,
M., Bertilsson, L., Mårtensson,
B., Scalia-Tomba, G.-P., Thorén, P., Träskman-Bendz, L.: CSF monoamine
metabolites in melancholia. Acta Psychiatr. Scand. 1984; 69: 201-219.
10.
Asnis, G.M., Eisenberg, J., van Praag, H.M., Lemus, C.Z., Friedman,
J.M.H., Miller, A.H.: The neuroendocrine response to fenfluramine in depressives
and normal controls. Biol. Psychiatry 1988; 24: 117-120.
11.
Avissar, S., Schreiber, G., Danon, A., Belmaker, R.H.: Lithium inhibits
adrenergic and cholinergic increases in GTP binding in rat cortex. Nature 1988;
331: 440-442.
12.
Avissar, S., Schreiber, G.: Muscarinic receptor subclassification and
G-proteins: significance for lithium action in affective disorders and for
treatment of the extrapyramidal side effects of neuroleptics. Biol. Psychiatry
1989; 26: 113-130.
13.
Avissar, S., Schreiber, G., Aulakh, C.S., Wozniak, K.M., Murphy, D.L.:
Carbamazepine and elektroconvulsive shock attenuate b-adrenoceptor
and muskarinic cholinoceptor coupling to G proteins in rat cortex. Eur. J.
Pharmacol. - Mol. Pharmacol. Sect. 1990; 189: 99-103.
14.
Avissar, S., Murphy, D.L., Schreiber, G.: Magnesium reversal of lithium
inhibition of b-adrenergic
and muscarinic receptor coupling to G proteins. Biochem. Pharmacol. 1991; 41
(2): 171-175.
15.
Avissar, S., Schreiber, G.: The involvement of guanine nucleotide binding
proteins in the pathogenesis and treatment of affective disorders. Biol.
Psychiatry 1992; 31: 435-459.
16.
Avissar, S.,
Nechamkin, Y., Roitman, G., Schreiber, G.: Reduced G protein functions and
immunoreactive levels in mononuclear leukocytes of patients with depression. Am.
J. Psychiatry 1997; 154: 211-217.
17.
Axelrod, J., Whitby, L.G., Hertting, G.: Effect of psychotropic drugs on
the uptake of H3-norepinephrine by tissues. Science 1961; 133 (3450):
383-384.
18.
Axelrod, J., Inscoe, J.K.: The uptake and binding of circulating
serotonin and the effect of drugs. J. Pharm. Exp. Ther. 1963; 141: 161-165.
19.
Axelrod, J.: Noradrenaline: fate and control of its biosynthesis. Science
1971; 173: 598-606.
20. Baastrup, P.C., Schou, M.: Lithium as a prophylactic agent. Its effect against
recurrent depressions and manic-depressive psychosis. Arch. Gen. Psychiatry
1967; 16: 162-172.
21.
Bakish, D., Cavazzoni, P., Chudzik, J., Ravindvan, A., Hrdina, P.D.:
Effects of selective serotonin reuptake inhibitors on platelet serotonin
parameters in major depressive disorder. Biol. Psychiatry 1997; 41 (2): 184-190.
22.
Banerjee, S.P., Kung, L.S., Riggi, S.J., Chanda, S.K.: Development of b-adrenergic
receptor subsensitivity by antidepressants. Nature 1977; 268: 455-456.
23.
Baraban, J.M., Worley, P.F., Snyder, S.H.: Second messenger system and
psychoactive drug action: focus on the phosphoinositide system and lithium. Am.
J. Psychiatry 1989; 146 (10): 1251-1260.
24.
Barden, N., Reul, J.M.H.M., Holsboer, F.: Do antidepressants stabilize
mood through actions on the hypothalamic-pituitary-adrenocortical system? TINS
1995; 18 (1): 6-11.
25.
Barden, N.: Modulation of glucocorticoid receptor gene expression by
antidepressant drugs. Pharmacopsychiat. 1996; 29 (1): 12-22.
26.
Bartholini, G., Lloyd, K.G., Scatton, B., Zivkovic, B., Morselli, P.L.:
The GABA hypothesis of depression and antidepressant drug action.
Psyhopharmacol. Bull. 1985; 21 (3): 385-388.
27.
Berridge, M.J., Downes, C.P., Hanley, M.R.: Lithium amplifies
agonist-dependent phosphatidylinositol responses in brain and salivary glands.
Biochem. J. 1982; 206: 587-595.
28.
Berridge, M.J., Irvine, R.F.: Inositol trisphosphate, a novel second
messenger in cellular signal transduction. Nature 1984; 312: 315-321.
29.
Berridge, M.J.: Inositol trisphosphate and diacylglycerol: two
interacting second messengers. Annu. Rev. Biochem. 1987; 56: 159-193.
30.
Berridge, M.J.: Inositol trisphosphate, calcium, lithium, and cell
signaling. JAMA 1989; 262 (13): 1834-1841.
31.
Berstein, G., Haga, T., Ichiyama, A.: Effect of the lipid environment on
the differential affinity of purified cerebral and atrial muscarinic
acetylcholine receptors for pirenzepine. Mol. Pharmacol. 1989; 36: 601-607.
32.
Berzewski, H., Van
Moffaert, M., Gagiano, C.A.: Efficacy and tolerability of reboxetine compared
with imipramine in a double-blind study in patients suffering from major
depressive episodes. Eur. Neuropsychopharmacol. 1997; 7 (Suppl. 1): S37-S47.
33.
Bevan, J.A., Bevan, R.D., Shreeve, S.M.: Variable receptor affinity
hypothesis. FASEB J. 1989; 3: 1696-1704.
34.
Bhat, G.B., Block, E.R.: Serotonin transport in reconstituted endothelial
cell plasma membrane proteoliposomes: effect of hypoxia. Am. J. Respir. Cell
Mol. Biol. 1992; 6: 633-638.
35.
Biegon, A., Grinspoon, A., Blumenfeld, B., Bleich, A., Apter, A., Mester,
R.: Increased serotonin 5-HT2 receptor binding on blood platelets of suicidal
men. Psychopharmacol. 1990; 100: 165-167.
36.
Birnbaumer, L., Abramowitz, J., Brown, A.M.: Receptor-effector coupling
by G proteins. Biochim. Biophys. Acta 1990; 1031: 163-224.
37.
Blackshear, M.A., Martin, L.L., Sanders-Bush, E.: Adaptive changes in the
5-HT2 binding site after chronic administration of agonists and
antagonists. Neuropharmacol. 1986; 25 (11): 1267-1271.
38.
Blier, P., de Montigny, C., Chaput, Y.: A role for the serotonin in the
mechanism of action of antidepressant treatments: preclinical evidence. J. Clin.
Psychiatry 1990; 51 (4, Suppl.): 14-20.
39.
Blier, P., Bouchard, C.: Effect of repeated electroconvulsive shocs on
serotonergic neurons. Eur. J. Pharmacol. 1992; 211: 365-373.
40.
Blier, P., de Montigny, C.: Current advantages and trends in the
treatment of depression. TiPS 1994; 15 (7): 220-226.
41.
Block, E., Edwards, D.:
Effects of plasma membrane fluidity on serotonin transport by endothelial cells.
Am. J. Physiol. 1987; 253: C672-C678.
42.
Borsini, F.: Balance between cortical 5-HT1A and 5-HT2
receptor function: hypothesis for a faster antidepressant action. Pharmacol.
Res. 1994; 30 (1): 1-11.
43.
Bowden, C.L., Brugger, A.M., Swan, A.C., Calabrese, J.R., Janicak, P.G.,
Petty, F., Dilsaver, S.C., Davis, J.M., Rush, A.J., Small, J.G., Garza-Trevino,
E.S., Risch, S.C., Goodnick, P.J., Morris, D.D.: Efficacy of divalproex vs
lithium and placebo in the treatment of mania. JAMA 1994; 271 (12): 918-924.
44.
Boyer, J.L., Waldo, G.L., Harden, T.K.: bg-subunit
activation of G-protein-regulated phospholipase C. J. Biol. Chem. 1992; 267
(35): 25451-25456.
45.
Brady, L.S.: Stress, antidepressant drugs, and the locus coeruleus. Brain
Res. Bull. 1994; 35 (5/6): 545-556.
46.
Bremner, J.D., Innis, R.B., Salomon, R.M., Staib, L.H., Ng, C.K., Miller,
H.L., Bronen, R.A., Krystal, J.H., Duncan, J., Rich, D., Price, L.H., Malison,
R., Dey, H., Soufer, R., Charney, D.S.: Positron emission tomography measurement
of cerebral metabolic correlates of tryptophan depletion-induced depressive
relapse. Arch. Gen. Psychiatry 1997; 54: 364-374.
47.
Brodie, B.B., Pletscher, A., Shore, P.A.: Evidence that serotonin has a
role in brain function. Science 1955; 122 (3177): 968.
48.
Broekkamp, C.L.E., Leysen, D., Peeters, B.W.M.M., Pinder, R.M.: Prospects
for improved antidepressants. J. Med. Chem. 1995; 38 (23): 4615-4633.
49.
Brunello, N., Barbaccia, M.L., Chuang, D.-M., Costa, E.: Down-regulation
of b-adrenergic
receptors following repeated injections of desmethylimipramine: permissive role
of serotonergic axons. Neuropharmacol. 1982; 21: 1145-1149.
50.
Bunney, W.E., Davis, J.M.: Norepinephrine in depressive reactions. Arch.
Gen. Psychiatry 1965; 13: 483-494.
51.
Caldecott-Hazard, S., Morgan, D.G., DeLeon-Jones, F., Overstreet, D.H.,
Janowsky, D.: Clinical and biochemical aspects of depressive disorders: II.
transmitter/receptor theories. Synapse 1991; 9: 251-301.
52.
Calogero, A.E., Bagdy, G., Moncada, M.L., D'Agata, R.: Effect of
selective serotonin agonists on basal, corticotrophin-releasing hormone- and
vasopressin-induced ACTH release in vitro
from rat pituitary cells. J. Endocrinol. 1993; 136: 381-387.
53.
Cantoni, G.L., Mudd, S.H., Andreoli, V.: Affective disorders and
S-adenosylmethionine: a new hypothesis. TINS 1989; 12 (9): 319-324.
54.
Carroll, B.J., Feinberg, M., Greden, J.F., Tarika, J., Albala, A.A.,
Hasket, R.G., James, N.M., Kronfol, Z., Lohr, N., Steiner, M., de Vigne, J.P.,
Young, E.: A specific laboratory test for the diagnosis of melancholia. Arch.
Gen. Psychiatry 1981; 38: 15-22.
55.
Carroll, B.J.: The dexamethasone suppression test for melancholia. Brit.
J. Psychiat. 1982; 140: 292-304.
56.
Casebolt, T.L., Jope, R.S.: Long-term lithium treatment selectively
reduces receptor-coupled inositol phospholipid hydrolysis in rat brain. Biol.
Psychiatry 1989; 25: 329-340.
57.
Casebolt,
T.L., Jope, R.S.: Effects of chronic lithium treatment on protein kinase C and
cyclic AMP-dependent protein phosphorylation. Biol. Psychiatry 1991; 29:
233-243.
58.
Cohen, L.J., De Vane, C.L.: Clinical implications of antidepressant
pharmacokinetics and pharmacogenetics. Ann. Pharmacother. 1996; 30 (12):
1471-1480.
59.
Colin, S.F., Chang, H.-C., Mollner, S., Pfeuffer, T., Reed, R.R., Duman,
R.S., Nestler, E.J.: Chronic lithium regulates the expression of adenylate
cyclase and Gi-protein a
subunit in rat cerebral cortex. Proc. Natl. Acad. Sci. USA 1991; 88:
10634-10637.
60.
Collier, D.A., Arranz, M.J., Sham, P., Battersby, S., Vallada, H., Gill,
P., Aitchison, K.J., Sodhi, M., Li, T., Roberts, G.W., Smith, B., Morton, J.,
Murray, R.M., Smith, D., Kirov, G.: The serotonin transporter is a potential
susceptibility factor for bipolar affective disorder. NeuroReport 1996; 7 (10):
1675-1679.
61.
Coppen, A., Shaw, D.M., Farrell, J.P.: Potentiation of the antidepressive
effect of a monoamine-oxidase inhibitor by tryptophan. Lancet 1963; i (7272):
79-81.
62.
Coppen, A.: The biochemistry of affective disorders. Brit. J. Psychiat.
1967; 113: 1237-1264.
63.
Cross, J.A., Horton, R.W.: Are increases in GABAB receptors
consistent findings following chronic antidepressant administration? Eur. J.
Pharmacol. 1987; 141: 159-162.
64.
Crow, T.J.: Nature of the
genetic contribution to psychotic illness - a continuum viewpiont. Acta
Psychiatr. Scand. 1990; 81: 401-408.
65.
Curtis, A.L., Valentino, R.J.: Corticotropin-releasing factor
neurotransmission in locus coeruleus: a possible site of antidepressant action.
Brain Res. Bull. 1994; 35 (5/6): 581-587.
66.
Dahlström, A., Fuxe, K.: Evidence for the existence of
monoamine-containing neurons in the central nervous system. I. Demonstration of
monoamines in the cell bodies of brain stem neurons. Acta Physiol. Scand. 1964;
62 (Suppl. 232): 1-55.
67.
Danjou, P., Hackett, D.: Safety and tolerance profile of venlafaxine.
Int. Clin. Psychopharmacol. 1995; 10 (Suppl. 2): 15-20.
68.
De Blasi, A., Lipartiti, M., Algeri, S., Sacchetti, G., Costantini, C.,
Fratelli, M., Cotecchia, S.: Stress induced desensitization of lymphocyte b-adrenoceptors
in young and aged rats. Pharmacol. Biochem. Behav. 1986; 24: 991-998.
69.
De Simoni, M.G., De Luigi, A., Clavenna, A., Manfridi, A.: In vivo
studies on the enhancement of serotonin reuptake by tianeptine. Brain Res. 1992;
574: 93-97.
70.
Deakin, J.F.W., Pennell, I., Upadhyaya, A.J., Lofthouse, R.: A
neuroendocrine study of 5HT function in depression: evidence for biological
mechanisms of endogenous and psychosocial causation. Psychopharmacol. 1990; 101:
85-92.
71.
deFelipe, M.D.C., Jiménez, I., Castro, A., Fuentes, J.A.: Antidepressant
action of imipramine and iprindole in mice is enhanced by inhibitors of
enkephalin-degrading peptidases. Eur. J. Pharmacol. 1989; 159: 175-180.
72.
Dennis, T., Beauchemin, V., Lavoie, N.: Antidepressant-induced modulation
of GABAA receptors and b-adrenoceptors
but not GABAB receptors in the frontal cortex of olfactory
bulbectomised rats. Eur. J. Pharmacol. 1994; 262 (1-2): 143-148.
73.
Depaermentier,
F., Cheetham, S.C., Crompton, M.R., Katona, C.L.E., Horton, R.W.: Brain b-adrenoceptor
binding sites in depressed suicide victims: effects of antidepressant treatment.
Psychopharmacol. 1991; 105 (2): 283-288.
74.
Dubovsky, S.L., Franks,
R.D.: Intracellular calcium ions in affective disorders: a review and
hypothesis. Biol. Psychiatry 1983; 18: 781-797.
75.
Duman, R.S., Heninger,
G.R., Nestler, E.J.: A molecular and cellular theory of depression. Arch. Gen.
Psychiatry 1997; 54: 597-606.
76.
Ebstein, R.P., Lerer, B., Shapira, B., Shemesh, Z., Moscovich, D.G.,
Kindler, S.: Cyclic AMP second-messenger signal amplification in depression.
Brit. J. Psychiat. 1988; 152: 665-669.
77.
Edwards, J.G.: Drug choice in depression: selective serotonin reuptake
inhibitors or tricyclic antidepressants? CNS Drugs 1995; 4 (2): 141-159.
78.
Ellis, P.M., Salmond, C.: Is platelet imipramine binding reduced in
depression? A meta-analysis. Biol. Psychiatry 1994; 36: 292-299.
79.
El-Mallakh, R.S., Wyatt, R.J.: The Na,K-ATPase hypothesis for bipolar
illness. Biol. Psychiatry 1995; 37: 235-244.
80.
Emrich, H.M., Zerssen, D.von, Kissling, W., Möller, H.-J., Windorfer,
A.: Effect of sodium valproate on mania. The GABA-hypothesis of affective
disorders. Arch. Psychiat. Nervenkr. 1980; 229: 1-16.
81.
Emrich, H.M., Günther, R., Dose, M.: Current perspectives in the
pharmacopsychiatry of depression and mania. Neuropharmacol. 1983; 22 (3B):
385-388.
82.
Engström, G., Alsen, M., Regnell, G., Traskman-Bendz, L.: Serum lipids
in suicide attempters. Suicide Life Threat. Behav. 1995; 25 (3): 393-400.
83.
Evans, D.L., Leserman, J., Pedersen, C.A., Golden, R.N., Lewis, M.H.,
Folds, J.A., Ozer, H.: Immune correlates of stress and depression.
Psychopharmacol. Bull. 1989; 25 (3): 319-324.
84.
Fattaccini, C.M., Bolaňos-Jimenez, F., Gozlan, H., Hamon, M.: Tianeptine
stimulates uptake of 5-hydroxytryptamine in
vivo in the rat brain. Neuropharmacol. 1990; 29 (1): 1-8.
85.
Fibiger, H.C.: Neurobiology of depression focus on dopamine. In: G.
Gessa, W. Fratta, L. Pani, G. Serra, eds. Depression and Mania: From
Neurobiology to treatment. New York: Raven Press, 1995; 1-17.
86.
Fišar, Z., Krulík, R.: Buněčné membrány a jejich interakce s
antidepresivy. Biol. listy 1995; 60 (2): 81-96.
87.
Fišar, Z., Krulík, R.,
Fuksová, K., Sikora, J.: Imipramine distribution among red blood cells, plasma
and brain tissue. Gen. Physiol. Biophys. 1996; 15: 51-64.
88.
Floreani, M., Bonetti, A.C., Carpenedo, F.: Increase of Na+/K+
ATPase activity in intact rat brain synaptosomes after their interaction
with phosphatidylserine vesicles. Biochem. Biophys. Res. Commun. 1981; 101 (4):
1337-1344.
89.
Floreani, M., Debetto, P., Carpenedo, F.: Phosphatidylserine vesicles
increase Ca2+ uptake by rat brain synaptosomes. Arch. Biochem.
Biophys. 1991; 285 (1): 116-119.
90.
Friedel, H.A., Goa, K.L., Benfield, P.: S-adenosyl-L-methionine. A review
of its pharmacological properties and therapeutic potential in liver dysfunction
and affective disorders in relation to its physiological role in cell
metabolism. Drugs 1989; 38 (3): 389-416.
91.
Fuller, R.W.: 5HT uptake mechanisms and drug development. In: S.Z.
Langer, N. Brunello, G. Racagni, J. Mendlewicz, eds. Serotonin Receptor
Subtypes: Pharmacological Significance and Clinical Implications. Int. Acad.
Biomed. Drug Res., vol. 1. Basel: Karger, 1992; 56-66.
92.
Fuxe, K., Grobecker, H.: The effect of b-phenylethylamine
on central and peripheral monoamine-containing neurons. Eur. J. Pharmacol. 1967;
2: 202-207.
93.
García-Sevilla, J.A., Zis, A.P., Hollingsworth, P.J., Greden, J.F.,
Smith, C.B.: Platelet a2-adrenergic receptors in major depressive disorder. Binding of tritiated
clonidine before and after tricyclic antidepressant drug treatment. Arch. Gen.
Psychiatry 1981a; 38: 1327-1333.
94.
García-Sevilla, J.A., Zis, A.P., Zelnik, T.C., Smith, C.B.: Tricyclic
antidepressant drug treatment decreases a2-adrenoreceptors
on human platelet membranes. Eur. J. Pharmacol. 1981b; 69: 121-123.
95.
García-Sevilla, J.A., Guimón, J., García-Vallejo, P., Fuster, M.J.:
Biochemical and functional evidence of supersensitive platelet a2-adrenoceptors in major affective disorder. Effect of long-term lithium
carbonate treatment. Arch. Gen. Psychiatry 1986; 43: 51-57.
96.
García-Sevilla, J.A., Padró, D., Giralt, T., Guimón, J., Areso, P.: a2-adrenoceptor-mediated inhibition of platelet adenylate cyclase and
induction of aggregation in major depression. Effect of long-term cyclic
antidepressant drug treatment. Arch. Gen. Psychiatry 1990; 47: 125-132.
97.
García-Sevilla, J.A., Escribá, P.V., Sastre, M., Walzer, C., Busquets,
X., Jaquet, G., Reis, D.J., Guimón, J.: Immunodetection and quantitation of
imidazoline receptor proteins in platelets of patients with major depression and
in brains of suicide victims. Arch. Gen. Psychiatry 1996; 53: 803-810.
98.
Gerner, R.H., Stanton, A.: Algorithm for patient management of acute
manic states: lithium, valproate, or carbamazepine? J. Clin. Psychopharmacol.
1992; 13 (1,Suppl.): 57S-63S.
99.
Gessa, G.L., Pani, L., Serra, G., Fratta, W.: Animal models of mania. In:
G. Gessa, W. Fratta, L. Pani, G. Serra, eds. Depression and Mania: From
Neurobiology to treatment. New York: Raven Press, 1995; 43-66.
100.
Gilad, G.M., Gilad, V.H.: Polyamines in neurotrauma. Ubiquitous molecules
in search of a function. Biochem. Pharmacol. 1992; 44 (3): 401-407.
101.
Gilad, G.M., Gilad, V.H., Casanova, M.F., Casero, R.A.: Polyamines and
their metabolizing enzymes in human frontal cortex and hippocampus: preliminary
measurements in affective disorders. Biol. Psychiatry 1995; 38: 227-234.
102.
Gillespie, D.D., Manier, D.H., Sanders-Bush, E., Sulser, F.: The
serotonin/norepinephrine-link in brain. II. Role of serotonin in the regulation
of beta adrenoceptors in the low agonist affinity conformation. J.
Pharm. Exp. Ther. 1988; 244 (1): 154-159.
103.
Gilman, A.G.: G proteins: transducers of receptor-generated signals.
Annu. Rev. Biochem. 1987; 56: 615-649.
104.
Glassman, A.: Indoleamines and affective disorders. Psychosom. Med. 1969;
31 (2): 107-114.
105.
Glowinski, J., Axelrod, J.: Inhibition of uptake of
tritiated-noradrenaline in the intact rat brain by imipramine and structurally
related compounds. Nature 1964; 204: 1318-1319.
106.
Greden, J.F., Gardner, R., King, D., Grunhaus, L., Carroll, B.J.,
Kronfol, Z.: Dexamethasone suppression tests in antidepressant treatment of
melancholia. The process of normalization and test-retest reproducibility. Arch.
Gen. Psychiatry 1983; 40: 493-500.
107.
Gyermek, L.: The pharmacology of imipramine and related antidepressants.
In: C.C. Pfeiffer, J.R. Smythies, eds. Int. Rev. Neurobiol., Vol. 9. New York
& London: Academic Press, 1966; 95-143.
108.
Hadcock, J.R., Malbon, C.C.: Down-regulation of b-adrenergic
receptors: agonist-induced reduction in receptor mRNA levels. Proc. Natl. Acad.
Sci. USA 1988; 85: 5021-5025.
109.
Hale, A.S., Hannah, P., Sandler, M., Bridges, P.K.: Tyramine conjugation
test for prediction of treatment response in depressed patients. Lancet 1989; i
(8632): 234-236.
110.
Hallcher, L.M., Sherman, W.R.: The effects of lithium ion and other
agents on the activity of myo-inositol-1-phosphatase
from bovine brain. J. Biol. Chem. 1980; 255 (22): 10896-10901.
111.
Harrison, W.M., Cooper, T.B., Steward, J.W., Quitkin, F.M., McGrath,
P.J., Liebowitz, M.R., Rabkin, J.R., Markowitz, J.S., Klein, D.F.: The tyramine
challenge test as a marker for melancholia. Arch. Gen. Psychiatry 1984; 41:
681-685.
112.
Healy, D.: Rhythm and blues. Neurochemical, neuropharmacological and
neuropsychological implications of a hypothesis of circadian rhythm dysfunction
in the affective disorders. Psychopharmacol. 1987; 93 (3): 271-285.
113.
Heninger, G.R., Charney, D.S., Sternberg, D.E.: Serotonergic function in
depression. Prolactin response to intravenous tryptophan in depressed patients
and healthy subjects. Arch. Gen. Psychiatry 1984; 41: 398-402.
114.
Heninger, G.R., Charney, D.S., Price, L.H.: a2-Adrenergic receptor sensitivity in depression. Arch. Gen. Psychiatry
1988; 45: 718-726.
115.
Heron, D., Shinitzky, M.,
Hershkowitz, M., Samuel, D.: Lipid fluidity markedly modulates the binding of
serotonin to mouse brain membranes. Proc. Natl. Acad. Sci. USA 1980; 77:
7463-7467.
116.
Hibbeln, J.R., Palmer, J.W., Davis, J.M.: Are disturbances in
lipid-protein interactions by phospholipase-A2 a predisposing factor
in affective illness? Biol. Psychiatry 1989; 25 (7): 945-961.
117.
Hibbeln, J.R., Salem,
N.Jr.: Dietary polyunsaturated fatty acids and depression: when cholesterol does
not satisfy. Am. J. Clin. Nutr. 1995; 62 (1): 1-9.
118.
Hightower, L.E.: Heat shock, stress proteins, chaperons, and
proteotoxicity. Cell 1991; 66: 191-197.
119.
Hjorth, S., Auerbach, S.B.: Lack of 5-HT1A
autoreceptor desensitization following chronic citalopram treatment, as
determined by in vivo microdialysis.
Neuropharmacol. 1994; 33 (3/4): 331-334.
1994
120.
Ho, A.P., Gillin, J.C., Buchsbaum, M.S., Wu, J.C., Abel, L., Bunney,
W.E.Jr.: Brain glucose metabolism during non-rapid eye movement sleep in major
depression. Arch. Gen. Psychiatry 1996; 53: 645-652.
121.
Hokin-Neaverson, M., Spiegel, D.A., Lewis, W.C.: Deficiency of
erythrocyte sodium pump activity in bipolar manic-depressive psychosis. Life
Sci. 1974; 15: 1739-1748.
122.
Holden, R.J.: Schizophrenia, suicide and the serotonin story. Med.
Hypoth. 1995; 44: 379-391.
123.
Holsboer, F., Lauer, C.J., Schreiber, W., Krieg, J.-C.: Altered
hypothalamic-pituitary-adrenocortical regulation in healthy subjects at high
familial risk for affective disorders. Neuroendocrinology 1995; 62 (4): 340-347.
124.
Höschl, C.: Neuroendokrinologie v psychiatrii. Avicenum, Zdravotnické
nakl., Praha, 1989. 232 s.
125.
Hsiao, J.K., Manji, H.K., Chen, G., Bitran, J.A., Risby, E.D., Potter,
W.Z.: Lithium administration modulates platelet Gi in humans. Life
Sci. 1992; 50: 227-233.
126.
Hudson, C.J., Young, L.T., Li, P.P., Warsh, J.J.: CNS signal transduction
in the pathophysiology and pharmacotherapy of affective disorders and
schizophrenia. Synapse 1993; 13: 278-293.
127.
Hyman, S.E., Nestler, E.J.: Initiation and adaptation: a paradigm for
understanding psychotropic drug action. Am. J. Psychiatry 1996; 153 (2):
151-162.
128.
Hyttel, J.: Pharmacological characterization of selective serotonin
reuptake inhibitors (SSRIs). Int. Clin. Psychopharmacol. 1994; 9 (Suppl. 1):
19-26.
129.
Chaput, Y., de Montigny, C., Blier, P.: Presynaptic and postsynaptic
modifications of the serotonin system by long-term administration of
antidepressant treatments. Neuropsychopharmacol. 1991; 5 (4): 219-229.
130.
Charney, D.S., Menkes, D.B., Heninger, G.R.: Receptor sensitivity and the
mechanism of action of antidepressat treatment. Implications for the etiology
and therapy of depression. Arch. Gen. Psychiatry 1981; 38: 1160-1180.
131.
Charney, D.S., Delgado, P.L.: Current concepts of the role of serotonin
function in depression and anxiety. In: S.Z. Langer, N. Brunello, G. Racagni, J.
Mendlewicz, eds. Serotonin Receptor Subtypes: Pharmacological Significance and
Clinical Implications. Int. Acad. Biomed. Drug Res., vol. 1. Basel: Karger,
1992; 89-104.
132.
Checkley, S.: Monoamines, depression and antidepressant drugs.
Pharmacopsychiat. 1988; 21: 6-8.
133.
Cheetham, S.C., Crompton, M.R., Katona, C.L.E., Horton, R.W.: Brain 5-HT2
receptor binding sites in depressed suicide victims. Brain Res. 1988a; 443:
272-280.
134.
Cheetham, S.C., Crompton, M.R., Katona, C.L.E., Parker, S.J., Horton,
R.W.: Brain GABAA/benzodiazepine binding sites and glutamic acid
decarboxylase activity in depressed suicide victims. Brain Res. 1988b; 460:
114-123.
135.
Cheetham, S.C., Crompton, M.R., Czudek, C., Horton, R.W., Katona, C.L.E.,
Reynolds, G.P.: Serotonin concentrations and turnover in brains of depressed
suicides. Brain Res. 1989; 502: 332-340.
136.
Cheetham, S.C., Crompton, M.R., Katona, C.L.E., Horton, R.W.: Brain 5-HT1
binding sites in depressed suicides. Psychopharmacol. 1990; 102: 544-548.
137.
Chen, J., Rasenick, M.M.: Chronic treatment of C6 glioma cells with
antidepressant drugs increases functional coupling between a G protein (Gs) and
adenylyl cyclase. J. Neurochem. 1995; 64 (2): 724-732.
138.
Chen, J., Rasenick, M.M.: Chronic antidepressant treatment facilitates G
protein activation of adenylyl cyclase without altering G protein content. J.
Pharm. Exp. Ther. 1995; 275 (1): 509-517.
139.
Janowsky, D.S., El-Yousef, M.K., Davis, J.M., Sekerke, H.J.: A
cholinergic-adrenergic hypothesis of mania and depression. Lancet 1972; ii:
632-635.
140.
Janowsky, A., Okada, F., Manier, D.H., Applegate, C.D., Sulser, F.: Role
of serotonergic input in the regulation of the b-adrenergic
receptor-coupled adenylate cyclase system. Science 1982; 218 (4575): 900-901.
141.
Joffe, R.T., Sokolov, S.T.: Thyroid hormones, the brain, and affective
disorders. Crit. Rev. Neurobiol. 1994; 8 (1-2): 45-63.
142.
Johnson, S.L., Roberts, J.E.: Life events and bipolar disorder:
implications from biological theories. Psychological Bull. 1995; 117: 434-449.
143.
Kapur, S., Mann, J.J.: Role of the dopaminergic system in depression.
Biol. Psychiatry 1992; 32: 1-17.
144.
Kellar, K.J., Bergstrom, D.A.: Electroconvulsive shock: effects on
biochemical correlates of neurotransmitter receptors in rat brain.
Neuropharmacol. 1983; 22 (3B): 401-406.
145.
Kellar, K.J.: Effects of electroconvulsive shock on noradrenergic and
serotonergic receptor in rat brain. Pharmacopsychiat. 1987; 20: 30-34.
146.
Kellar, K.J., Stockmeier, C.A., Martino, A.M.: Regulation of beta
adrenergic and serotonin-S2 receptors in brain by electroconvulsive
shock and serotonin. In: Dahl, Gram, Paul, Potter, eds. Clinical Pharmacology in
Psychiatry (Psychopharmacology Series 3). Berlin, Heidelberg: Springer-Verlag,
1987; 100-106.
147.
Kendler, K.S., Kessler, R.C., Walters, E.E., MacLean, C., Neale, M.C.,
Heath, A.C., Eaves, L.J.: Stressful life events, genetic liability, and onset of
an episode of major depression in woman. Am. J. Psychiatry 1995; 152: 833-842.
148.
Kling, M.A., Perini, G.I., Demitrack, M.A., Geracioti, T.D., Linnoila,
M., Chrousos, G.P., Gold, P.W.: Stress-responsive neurohormonal systems and the
symptom complex of affective illness. Psychopharmacol. Bull. 1989; 25 (3):
312-318.
149.
Kopin, I.J.: Storage and metabolism of catecholamines: the role of
monoamine oxidase. Pharmacol. Rev. 1964; 16: 179-191.
150.
Kopin, I.J.: Catecholamine metabolism: basic aspects and clinical
significance. Pharmacol. Rev. 1985; 37 (4): 333-364.
151.
Kreiss, D.S., Lucki, I.: Effects of acute and repeated
administration of antidepressant drugs on extracellular levels of
5-hydroxytryptamine measured in vivo.
J. Pharm. Exp. Ther. 1995; 274 (2): 866-876.
152.
Kronfol, Z., Silva, J., Greden, J., Dembinski, S., Gardner, R., Carroll,
B.: Impaired lymphocyte function in depressive illness. Life Sci. 1983; 33:
241-247.
153.
Krulík, R., Farská, I.:
Receptory - membránová struktura. I. Čs. Psychiat. 1983; 79 (5): 295-305.
154.
Kunugi, H., Takei, N., Aoki, H., Nauko, S.: Low serum cholesterol in
suicide attempters. Biol. Psychiatry 1997; 41 (2): 196-200.
155.
Kunz, M., Sikora, J., Krakowski, M., Convit, A., Cooper, T., Volavka, J.:
Serotonin in violent patients with schizophrenia. Psychiatry Res. 1995; 59:
161-163.
156.
Kuroda, Y., Watanabe, Y., McEwen, B.S.: Tianeptine decreases both
serotonin transporter mRNA and binding sites in rat brain. Eur. J. Pharmacol. -
Mol. Pharmacol. Sect. 1994; 268 (1): R3-R5.
157.
Lachman, H.M., Papolos, D.F.: Abnormal signal transduction: a
hypothetical model for bipolar affective disorder. Life Sci. 1989; 45 (16):
1413-1426.
158.
Lachman, H.M., Papolos, D.F.: A molecular model for bipolar affective
disorder. Med. Hypoth. 1995; 45 (3): 255-264.
159.
Langer, S.Z.: Presynaptic regulation of catecholamine release. Biochem.
Pharmacol. 1974; 23: 1793-1800.
160.
Langer, S.Z.: Presynaptic regulation of the release of catecholamines.
Pharmacol. Rev. 1981; 32 (4): 337-362.
161.
Langer, S.Z., Raisman, R., Tahraoui, L., Scatton, B., Niddam, R., Lee,
C.R., Claustre, Y.: Substituted tetrahydro-b-carbolines
are possible candidates as endogenous ligand of the [3H]imipramine
recognition site. Eur. J. Pharmacol. 1984; 98: 153-154.
162.
Langer, S.Z.: 25 Years
since the discovery of presynaptic receptors: present knowledge and future
perspectives. TiPS 1997; 18: 95-99.
163.
Lapin, I.P., Oxenkrug, G.F.: Intensification of the central
serotoninergic processes as a possible determinant of the thymoleptic effect.
Lancet 1969; i: 132-136.
164.
Lefkowitz, R.J.: G protein-coupled receptor kinases. Cell 1993; 74:
409-412.
165.
Lerer, B., Jabotinsky-Rubin, K., Bannet, J., Ebstein, R.P.:
Electroconvulsive shock prevents dopamine receptor supersensitivity. Eur. J.
Pharmacol. 1982; 80: 131-134.
166.
Lerer, B.: Studies on the role of brain cholinergic systems in the
therapeutic mechanisms and adverse effects of ECT and lithium. Biol. Psychiatry
1985; 20: 20-40.
167.
Lesch, K.P., Diesselkamp-Tietze, J., Schmidtke, A.: 5-HT1A
receptor function in depression: effect of chronic amitriptyline treatment. J.
Neural Transm. [Gen.Sect.] 1990a; 80: 157-161.
168.
Lesch, K.-P., Poten, B., Söhnle, K., Schulte, H.M.: Pharmacology of the
hypothermic response to 5-HT1A receptor activation in humans. Eur. J.
Clin. Pharmacol. 1990b; 39: 17-19.
169.
Lester, D.: The concentration of neurotransmitter metabolites in the
cerebrospinal fluid of suicidal individuals: a meta-analysis. Pharmacopsychiat.
1995; 28: 45-50.
170.
Lewy, A.J., Nurnberger,
J.I.Jr., Wehr, T.A., Pack, D., Becker, L.E., Powell, R.-L., Newsome, D.A.:
Supersensitivity to light: possible trait marker for manic-depressive illness.
Am. J. Psychiatry 1985; 142: 725-727.
171.
Leysen, D., Pinder, R.M.: Toward third generation antidepressants. Annu.
Rep. Med. Chem. (Sect. 1) 1994, 29: 1-12.
172.
Li, P.P., Tam, Y.-K., Young, L.T., Warsh, J.J.: Lithium decreases Gs,
Gi-1 and Gi-2 a-subunit
mRNA levels in rat cortex. Eur. J. Pharmacol. 1991; 206: 165-166.
173.
Lipinski, J.F., Cohen, B.M.: Minireview - adrenoreceptors and the
pharmacology of affective illness: a unifying theory. Life Sci. 1987; 40:
1947-1963.
174.
Lloyd, K.G., Morselli, P.L., Bartholini, G.: GABA and affective
disorders. Med. Biol. 1987; 65: 159-165.
175.
Lloyd, K.G., Pichat, P., Scatton, B., Zivkovic, B., Morselli, P.L.,
Bartholini, G.: The psychopharmacology of GABA synapses: update 1989. J. Neural
Transm. 1990; 29 (Suppl.): 13-28.
176.
Louilot, A., Mocaer, E., Simon, H., Le Moal, M.: Difference in the
effects of the antidepressant tianeptine on dopaminergic metabolism in the
prefrontal cortex and the nucleus accumbens of the rat. A voltammetric study.
Life Sci. 1990; 47: 1083-1089.
177.
Lucca, A., Lucini, V., Catalano, M., Smeraldi, E.: Neutral amino acid
availability in two major psychiatric disorders. Prog. Neuro-Psychopharmacol.
Biol. Psychiat. 1995; 19 (4): 615-626.
178.
Lund, A., Mjellem, N.: Chronic, combined treatment with desipramine and
mianserin: enhanced 5-HT1A receptor function and altered 5-HT1A/5-HT2
receptor interaction in rats. Pharmacol. Biochem. Behav. 1993; 45: 777-783.
179.
Maas, J.W.: Biogenic amines and depression. Biochemical and
pharmacological separation of two types of depression. Arch. Gen. Psychiatry
1975; 32: 1357-1361.
180.
Maes, M., Jacobs, M.-P., Suy, E., Minner, B., Leclercq, C., Christiaens,
F., Raus, J.: Suppressant effects of dexamethasone on the availability of plasma
L-tryptophan and tyrosine in healthy controls and in depressed patients. Acta
Psychiatr. Scand. 1990; 81: 19-23.
181.
Maes, M., Vandervorst, C., Suy, E., Minner, B., Raus, J.: A multivariate
study of simultaneous escape from suppression by dexamethasone of urinary free
cortisol, plasma cortisol, adrenocorticotropic hormone and b-endorphin
in melancholic patients. Acta Psychiatr. Scand. 1991; 83: 480-491.
182.
Maes, M., Stevens, W., DeClerck, L., Bridts, C., Peeters, D., Schotte,
C., Cosyns, P.: Immune disorders in depression: higher T helper/T
suppressor-cytotoxic cell ratio. Acta Psychiatr. Scand. 1992; 423-431: 86 (6).
183.
Maes, M., Meltzer, H., Jacobs, J., Suy, E., Calabrese, J., Minner, B.,
Raus, J.: Autoimmunity in depression: increased antiphospholipid autoantibodies.
Acta Psychiatr. Scand. 1993; 87 (3): 160-166.
184.
Maes, M., Delanghe, J.,
Meltzer, H.Y., Scharpé, S., D'Hondt, P., Cosyns, P.: Lower degree of
esterification of serum cholesterol in depression: relevance for depression and
suicide research. Acta Psychiatr. Scand. 1994; 90 (4): 252-258.
185.
Maes, M.: Evidence for an immune response in major depression: a review
and hypothesis. Prog. Neuro-Psychopharmacol. Biol. Psychiat. 1995; 19: 11-38.
186.
Maes, M., Melzer, H.Y.: The serotonin hypothesis of major depression. In:
F.E. Bloom, D.J. Kupfer, eds. Psychopharmacology: The Fourth Generation of
Progress. New York: Raven Press, 1995; 933-944.
187.
Maes, M., Meltzer, H.Y., D'Hondt, P., Cosyns, P., Blockx, P.: Effects of
serotonin precursors on the negative feedback effects of glucocorticoids on
hypothalamic-pituitary-adrenal axis function in depression.
Psychoneuroendocrinol. 1995a; 20 (2): 149-167.
188.
Maes, M., Wauters, A., Neels, H., Scharpé, S., Van Gastel, A., D'Hondt,
P., Peeters, D., Cosyns, P., Desnyder, R.: Total serum protein and serum protein
fractions in depression: relationships to depresive symptoms and glukocorticoid
activity. J. Affect. Disord. 1995b; 34: 61-69.
189.
Maes, M., Meltzer, H.Y.,
Bosmans, E., Bergmans, R., Vandoolaeghe, E., Ranjan, R., Desnyder, R.: Increased
plasma concentrations of interleukin-6, soluble interleukin-6, soluble
interleukin-2 and transferrin receptor in major depression. J. Affect. Disord.
1995c; 34: 301-309.
190.
Mandell, A.J.:
Non-equilibrium behavior of some brain enzyme and receptor systems. Annu. Rev.
Pharmacol. Toxicol. 1984; 24: 237-274.
191.
Manier, D.H., Gillespie, D.D., Sulser, F.:
5,7-Dihydroxytryptamine-induced lesions of serotonergic neurons and
desipramine-induced down-regulation of cortical beta adrenoceptors: a
re-evaluation. Biochem. Pharmacol. 1987; 36 (19): 3308-3310.
192.
Manji, H.K., Hsiao, J.K., Risby, E.D., Oliver, J., Rudorfer, M.V.,
Potter, W.Z.: The mechanisms of action of lithium. I. Effects on serotonergic
and noradrenergic systems in normal subjects. Arch. Gen. Psychiatry 1991; 48:
505-512.
193.
Manji, H.K.: G proteins: implications for psychiatry. Am. J. Psychiatry
1992; 149 (6): 746-760.
194.
Manji, H.K., Potter, W.Z., Lenox, R.H.: Signal transduction pathways.
Molecular target for lithium's actions. Arch. Gen. Psychiatry 1995; 52: 531-543.
195.
Manji, H.K., Bersudsky, Y., Chen, G., Belmaker, R.H., Potter, W.Z.:
Modulation of protein kinase C isozymes and substrates by lithium: the role of
myo-inositol. Neuropsychopharmacol. 1996; 15 (4): 370-381.
196.
Mann, J.J., Stanley, M., McBride, P.A., McEwen, B.S.: Increased serotonin
and b-adrenergic
receptor binding in the frontal cortices of suicide victims. Arch. Gen.
Psychiatry 1986; 43: 954-959.
197.
Mann, J.J., Kapur, S.: A dopaminergic hypothesis of major depression.
Clin. Neuropharmacol. 1995; 18 (Suppl. 1): S57-S65.
198.
Mann, J.J., Malone, K.M., Diehl, D.J., Perel, J., Cooper, T.B., Mintun,
M.A.: Demonstration in vivo of reduced serotonin responsivity in the brain of
untreated depressed patients. Am. J. Psychiatry 1996; 153: 174-182.
199.
Marazziti, D., Lenzi, A., Cassano, G.B.: Serotoninergic dysfunction in
bipolar disorder. Pharmacopsychiat. 1991; 24: 164-167.
200.
Masana, M.I., Bitran, J.A., Hsiao, J.K., Potter, W.Z.: In vivo evidence
that lithium inactivates Gi modulation of adenylate cyclase in brain.
J. Neurochem. 1992; 59: 200-205.
201.
Matsubara, S., Arora, R.C:, Meltzer, H.Y.: Serotonergic measures in
suicide brain: 5-HT1A binding sites in frontal cortex of suicide
victims. J. Neural Transm. [Gen.Sect.] 1991; 85: 181-194.
202.
Mayersohn, M., Guentert, T.W.: Clinical pharmacokinetics of the monoamine
oxidase-A inhibitor moclobemide. Clin. Pharmacokin. 1995; 29 (5): 292-332.
203.
McElroy, S.L., Keck, P.E., Pope, H.G., Hudson, J.I.: Valproate in the
treatment of bipolar disorder: literature review and clinical guidelines. J.
Clin. Psychopharmacol. 1992; 12 (1,Suppl.): 42S-52S.
204.
Meana, J.J., Barturen, F., García-Sevilla, J.A.: a2-Adrenoceptors in the brain of suicide victims: increased receptor
density associated with major depression. Biol. Psychiatry 1992; 31 (5):
471-490.
205.
Mellerup, E., Langer, S.Z., et al.: Validity of imipramine platelet
binding sites as biological marker of endogenous depression. A World Health
Organization collaborative study. Pharmacopsychiat. 1990; 23: 113-117.
206.
Meltzer, H.Y., Lowy, M.T.: The serotonin hypothesis of depression. In:
H.Y. Meltzer, ed. Psychopharmacology: The Third Generation of Progress. New
York: Raven Press, 1987; 513-526.
207.
Mendels, J., Frazer, A.: Alterations in cell membrane activity in
depression. Am. J. Psychiatry 1974; 131: 1240-1246.
208.
Menkes, D.B., Rasenick, M.M., Wheeler, M.A., Bitensky, M.V.: Guanosine
triphosphate activation of brain adenylate cyclase: enhancement by long-term
antidepressant treatment. Science 1983; 219 (4580): 65-67.
209.
Mennini, T., Mocaer, E., Garattini, S.: Tianeptine, a selective enhancer
of serotonin uptake in rat brain. Naunyn-Schmiedeberg's Arch. Pharmacol. 1987;
336: 478-482.
210.
Meyerson, L.R., Wennogle, L.P., Abel, M.S., Coupet, J., Lippa, A.S.,
Rauh, C.E., Beer, B.: Human brain receptor alterations in suicide victims.
Pharmacol. Biochem. Behav. 1982; 17: 159-163.
211.
Miller, H.L., Delgado, P.L., Salomon, R.M., Berman, R., Krystal, J.H.,
Heninger, G.R., Charney, D.S.: Clinical and biochemical effects of catecholamine
depletion on antidepressant-induced remission of depression. Arch. Gen.
Psychiatry 1996; 53: 117-128.
212.
Milligan, G., Green, A.: Agonist control of G-protein levels. TiPS 1991;
12: 207-209.
213.
Minneman, K.P., Dibner, M.D., Wolfe, B.B., Molinoff, P.B.: b1- and b2-adrenergic
receptors in rat cerebral cortex are independently regulated. Science 1979; 204
(4395): 866-868.
214.
Mitchell, P.B., Manji, H.K., Chen, G., Jolkovsky, L., Smith-Jackson, E.,
Denicoff, K., Schmidt, M., Potter, W.Z.: High levels of Gasaa
in platelets of euthymic patients with bipolar affective disorder. Am. J.
Psychiatry 1997; 154: 218-223.
215.
Moldin, S.O., Reich, T., Rice, J.P.: Current perspectives on the genetics
of unipolar depression. Behav. Gen. 1991; 21 (3): 211-242.
216.
Mongeau, R., Blier, P., de Montigny, C.: Electrophysiological assesment
of the implication of a2-adrenergic
heteroreceptors on serotonin terminals in the mechanism of action of
antidepressant drugs. In: S.Z. Langer, N. Brunello, G. Racagni, J. Mendlewicz,
eds. Critical Issues in the Treatment of Affective Disorders. Int. Acad. Biomed.
Drug Res., vol. 9. Basel: Karger, 1994; 98-109.
217.
Mons, N., Cooper, D.M.F.: Adenylate cyclases: critical foci in neuronal
signaling. TINS 1995; 18 (12): 536-542.
218.
Montgomery, S.A., Henry, J., McDonald, G., Dinan, T., Lader, M.,
Hindmarch, I., Clare, A., Nutt, D.: Selective serotonin reuptake inhibitors:
meta-analysis of discontinuation rates. Int. Clin. Psychopharm. 1994; 9: 47-53.
219.
Montgomery, S.A.: Rapid onset of action of venlafaxine. Int. Clin.
Psychopharmacol. 1995; 10 (Suppl. 2): 21-27.
220.
Montgomery, S.A.: Is there
a role for a pure noradrenergic drug in the treatment of depression? Eur.
Neuropsychopharmacol. 1997; 7 (Suppl. 1): S3-S9.
221.
Moore, C.M., Christensen, J.D., Lafer, B., Fava, M., Renshaw, P.F.: Lower
levels of nucleoside triphosphate in the basal ganglia of depressed subjects: a
phosphorus-31 magnetic resonance spectroscopy study. Am. J. Psychiatry 1997;
154: 116-118.
222.
Mørk,
A., Geisler, A., Hollund, P.: Effects of lithium on second messenger system in
the brain. Pharmacol. Toxicol. 1992; 71 (Suppl. I): 4-17.
223.
Motohashi, N., Ikawa, K., Kariya, T.: GABAB receptors are
upregulated by chronic treatment with lithium or carbamazepine. GABA hypothesis
of affective disorders? Eur. J. Pharmacol. 1989; 166: 95-99.
224.
Mueller,
P.S., Davis, J.M., Bunney, W.E.Jr., Weil-Malherbe, H., Cardon, P.V.: Plasma free
fatty acids concentration in depressive illness. Arch. Gen. Psychiatry 1970; 22:
216-221.
225.
Müller, N.: Psychoneuroimmunology. Implications for the drug treatment
of psychiatric disorders. CNS Drugs 1995; 4 (2): 125-140.
226.
Mysliveček, J.: Receptory - součást jedné z cest komunikace mezi buňkami.
Čs. Fyziol. 1996a; 45 (2): 99-111.
227.
Mysliveček, J.: Regulační mechanismy přenosu signálu receptory. Čs.
Fyziol. 1996b; 45 (4): 190-202.
228. Náhunek, K., Švestka, J., Ryšánek, R.: Volba antidepresiv u endogenní deprese podle klinických parametrů pro léčebné a profylaktické použití. Čs. Psychiat. 1986; 82 (5): 275-281.
229.
Nakamura, S.: Effects of phospholipase A2 inhibitors on the
antidepressant-induced axonal regeneration of noradrenergic locus coeruleus
neurons. Microscopy Res. Technique 1994; 29: 204-210.
230.
Nemeroff, C.B., Widerlöv, E., Bissette, G., Walléus, H., Karlsson, I.,
Eklund, K., Kilts, C.D., Loosen, P.T., Vale, W.: Elevated concentrations of CSF
corticotropin-releasing factor-like immunoreactivity in depressed patients.
Science 1984; 226 (4680): 1342-1344.
231.
Nemeroff, C.B., Owens, M.J., Bissette, G., Andorn, A.C., Stanley, M.:
Reduced corticotropin releasing factor binding sites in the frontal cortex of
suicide victims. Arch. Gen. Psychiatry 1988; 45: 577-579.
232.
Nemeroff, C.B. Knight, D.L., Franks, J., Craighead, W.E., Krishnan,
K.R.R.: Further studies on platelet serotonin transporter binding in depression.
Am. J. Psychiatry 1994; 151 (11): 1623-1625.
233.
Nestler, E.J., Terwilliger, R.Z., Duman, R.S.: Chronic antidepressant
administration alters the subcellular distribution of cyclic AMP-dependent
protein kinase in rat frontal cortex. J. Neurochem. 1989; 53 (5): 1644-1647.
234.
Nishizuka, Y.: Studies and perspectives of protein kinase C. Science
1986; 233 (4761): 305-312.
235.
Nishizuka, Y.: Protein kinase C and lipid signaling for sustained
cellular responses. FASEB J. 1995; 9: 484-496.
236.
Nowak, G., Layer, R.T., Skolnick, P., Paul, I.A.: Adaptation of the
N-methyl-D-aspartate receptor following chronic antidepressants. J. Neurochem.
1993; 61 [Suppl]: S51.
237.
Okada, F., Tokumitsu, Y., Ui, M.: Desensitization of b-adrenergic
receptor-coupled adenylate cyclase in cerebral cortex after in vivo treatment of
rats with desipramine. J. Neurochem. 1986; 47: 454-459.
238.
Okada, F., Tokumitsu, Y., Ui, M.: Possible involvement of pertussis toxin
substrates (Gi, Go) in desipramine-induced refractoriness of adenylate cyclase
in cerebral cortices of rats. J. Neurochem. 1988; 51: 194-199.
239.
Oren, D.A.: Retinal melatonin and dopamine in seasonal affective
disorder. J. Neural Transm. [Gen.Sect.] 1991; 83 (1-2): 85-95.
240.
Overstreet, D.H., Russell, R.W., Crocker, A.D., Schiller, G.D.: Selective
breeding for differences in cholinergic function: pre- and post-synaptic
mechanisms involved in sensitivity to anticholinesterase. Brain Res. 1984; 294:
227-232.
241.
Overstreet, D.H., Russell, R.W., Crocker, A.D., Gillin, J.C., Janowsky,
D.S.: Genetic and pharmacological models of cholinergic supersensitivity and
affective disorders. Experientia 1988; 44: 465-472.
242.
Owens, M.J., Nemeroff, C.B.: Role of serotonin in the pathophysiology of
depression: focus on the serotonin transporter. Clin. Chem. 1994; 40 (2):
288-295.
243.
Ozawa, H., Katamura, Y.,
Hatta, S., Amemiya, N., Saito, T., Ohshika, H., Takahata, N.: Antidepressants
directly influence in situ binding of guanine nucleotide in synaptic membrane.
Life Sci. 1994; 54 (13): 925-932.
244.
Pandey, G.N., Pandey, S.C., Isaac, L., Davis, J.M.: Effect of
electroconvulsive shock on 5-HT2 and a1-adrenoceptors
and phosphoinositide signalling system in rat brain. Eur. J. Pharmacol. 1992;
226 (4): 303-310.
245.
Pandey, G.N., Pandey, S.C., Dwivedi, Y., Sharma, R.P., Janicak, P.G.,
Davis, J.M.: Platelet serotonin-2A receptors: a potential biological marker for
suicidal behavior. Am. J. Psychiatry 1995; 152 (6): 850-855.
246.
Pare, C.M.B., Sandler, M.: A clinical and biochemical study of a trial of
iproniazid in the treatment of depression. J. Neurol. Neurosurg. Psychiat. 1959;
22: 247-251.
247.
Paul, I.A., Nowak, G., Layer, R.T., Popik, P., Skolnick, P.: Adaptation
of the N-methyl-D-aspartate receptor complex following chronic antidepressant
treatments. J. Pharm. Exp. Ther. 1994; 269 (1): 95-102.
248.
Penttinen, J.: Hypothesis:
low serum cholesterol, suicide, and interleukin-2. Am. J. Epidemiol. 1995; 141
(8): 716-718.
249.
Peričić, D., Manev, H.:
Behavioural evidence for simultaneous dual changes of 5-HT receptor subtypes:
mode of antidepressant action? Life Sci. 1988; 42: 2593-2601.
250.
Perry, K.W., Fuller, R.W.:
Effect of fluoxetine on serotonin and dopamine concentration in microdialysis
fluid from rat striatum. Life Sci. 1992; 50: 1683-1690.
251.
Petty, F.: GABA and mood disorders: a brief review and hypothesis. J.
Affect. Disord. 1995; 34: 275-281.
252.
Petty, F., Trivedi, M.H., Fulton M., Rush, A.J.: Benzodiazepines as
antidepressants: does GABA play a role in depression? Biol. Psychiatry 1995; 38:
578-591.
253.
Petty, F., Davis, L.L., Kabel, D., Kramer, G.L.: Serotonin dysfunction
disorders: a behavioral neurochemistry perspective. J. Clin. Psychiatry 1996; 57
(Suppl. 8): 11-16.
254.
Piletz, J.E., Schubert, D.S.P., Halaris, A.: Evaluation of studies on
platelet alpha2 adrenoreceptors in depressive illness. Life Sci. 1986; 39:
1589-1616.
255.
Piñeyro,
G., Blier, P., Dennis, T., de Montigny, C.: Desensitization of the neuronal 5-HT
carrier following its long-term blockade. J. Neurosci. 1994; 14 (5): 3036-3047.
256.
Poirier-Littre, M.F.: Vulnerabilite biologique aux troubles depressifs.
Encephale 1994; 20 (4): 629-638.
257.
Popoli, M., Vocaturo, C., Perez, J., Smeraldi, E., Racagni, G.:
Presynaptic Ca2+/calmodulin-dependent protein kinase II:
autophosphorylation and activity increase in the hippocampus after long-term
blockade of serotonin reuptake. Mol. Pharmacol. 1995; 48 (4): 623-629.
258.
Potter, W.Z., Manji, H.K.: Catecholamines in depression: an update. Clin.
Chem. 1994a; 40 (2): 279-287.
259.
Potter, W.Z., Manji, H.K.: Clinical onset of antidepressant action:
implications for new drug development. In: S.Z. Langer, N. Brunello, G. Racagni,
J. Mendlewicz, eds. Critical Issues in the Treatment of Affective Disorders.
Int. Acad. Biomed. Drug Res. vol. 9. Basel: Karger, 1994b; 118-126.
260.
Prange, A.J., Jr.: The pharmacology and biochemistry of depression. Dis.
Nerv. Syst. 1964; 25: 217-221.
261.
Prange, A.J., Wilson, I.C., Lynn, C.W., Alltop, L.B., Stikeleather, R.A.:
L-tryptophan in mania. Contribution to a permissive hypothesis of affective
disorders. Arch. Gen. Psychiatry 1974; 30: 56-62.
262.
Praško, J.: Fototerapie a
cirkadiánní rytmy u depresivních poruch. "Zprávy" č. 97. Praha, Výzkumný
ústav psychiatrický, 1990, 128 s.
263.
Price, L.H., Charney, D.S., Rubin, A.L., Heninger, G.R.: a2-Adrenergic receptor function in depression. The cortisol response to
yohimbine. Arch. Gen. Psychiatry 1986; 43: 849-858.
264.
Purba, J.S., Hoogendijk, W.J.G., Hofman, M.A., Swaab, D.F.: Increased
number of vasopressin- and oxytocin-expressing neurons in the paraventricular
nucleus of the hypothalamus in depression. Arch. Gen. Psychiatry 1996; 53:
137-143.
265.
Racagni, G., Mocchetti, I., Calderini, G., Battistella, A., Brunello, N.:
Temporal sequence of changes in central noradrenergic system of rat after
prolonged antidepressant treatment: receptor desensitization and
neurotransmitter interactions. Neuropharmacol. 1983; 22 (3B): 415-424.
266.
Racagni, G., Brunello, N.: Transynaptic mechanisms in the action of
antidepressant drugs. Trends Pharmacol. Sci. 1984; 5 (12): 527-531.
267.
Racagni, G., Brunello, N., Tinelli, D., Perez, J.: New biochemical
hypotheses on the mechanism of action of antidepressant drugs: cAMP - dependent
phosphorylation system. Pharmacopsychiat. 1992; 25: 51-55.
268.
Raiteri, M., Maura, G., Folghera, S., Cavazzani, P., Andrioli, G.C.,
Schlicker, E., Schalnus, R., Göthert, M.: Modulation of 5-hydroxytryptamine in
the human cerebral cortex. Naunyn-Schmiedeberg's Arch. Pharmacol. 1990; 342:
508-512.
269.
Ram, A., Guedj, F., Cravchic, A., Weinstein, L., Cao, Q., Badner, J.A.,
Goldin, L.R., Grisaru, N., Manji, H.K., Belmaker, R.H., Gershon, E.S., Gejman,
P.V.: No abnormality in the gene for the G protein stimulatory a subunit in
patients with bipolar disorder. Arch. Gen. Psychiatry 1997; 54: 44-48.
270.
Randrup, A., Munkvad, I., Fog, R., Gerlach, J., Molander, L., Kjellberg,
B., Scheel-Krüger, J.: Mania, depression, and brain dopamine. In: W.B. Essman,
L. Valzelli, eds. Curr. Dev. Psychopharmacol., Vol. 2. New York: Spectrum Publ.,
1975; 205-248.
271.
Rasenick, M.M., Stein, P.J., Bitensky, M.W.: The regulatory subunit of
adenylate cyclase interacts with cytoskeletal components. Nature 1981; 294
(5841): 560-562.
272.
Reddy, P.L., Khanna, S., Subhash, M.N., Channabasavanna, S.M., Rao,
B.S.S.R.: CSF amine metabolites in depression. Biol. Psychiatry 1992a; 31:
112-118.
273.
Reddy, P.L., Khanna, S., Subhash, M.N., Channabasavanna, S.M., Rao,
B.S.S.R.: Erythrocyte membrane sodium-potassium adenosine triphosphatase
activity in affective disorders. J. Neural Transm. [Gen.Sect.] 1992b; 89 (3):
209-218.
274.
Reveley, M.A., Glover, V., Sandler, M., Coppen, A.: Increased platelet
MAO activity in affective disorders. Psychopharmacol. 1981; 73: 257-260.
275.
Rice, J., Reich, T., Andreasen, N.C., Endicott, J., Van Eerdewegh, M.,
Fishman, R., Hirschfeld, R.M.A., Klerman, G.L.: The familial transmission of
bipolar illness. Arch. Gen. Psychiatry 1987; 44: 441-447.
276.
Richelson, E.: Antidepressants and brain neurochemistry. Mayo Clin. Proc.
1990; 65: 1227-1236.
277.
Richelson, E.: Pharmacology of antidepressants - characteristics of the
ideal drug. Mayo Clin. Proc. 1994; 69: 1069-1081.
278.
Risby, E.D., Hsiao, J.K., Manji, H.K., Bitran, J:, Moses, F., Zhou, D.F.,
Potter, W.Z.: The mechanism of action of lithium. II. Effects on adenylate
cyclase activity and b-adrenergic
receptor binding in normal subjects. Arch. Gen. Psychiatry 1991; 48: 513-524.
279.
Rosenblatt, S., Chanley, J.D., Sobotka, H., Kaufman, M.R.:
Interrelationships between electroshock, the blood‑brain barrier, and
catecholamines. J. Neurochem. 1960; 5: 172-176.
280. Rosenthal, N.E., Sack, D.A., Gillin, J.C., Lewy, A.J., Goodwin, F.K., Davenport, Y., Mueller, P.S., Newsome, D.A., Wehr, T.A.: Seasonal affective disorder. A description of the syndrome and preliminary findings with light therapy. Arch. Gen. Psychiatry 1984; 41: 72-80.
281.
Rosenthal, N.E., Sack, D.A., Carpenter, C.J., Parry,
B.L., Mendelson, W.B., Wehr, T.A.: Antidepressant effects of light in seasonal
affective disorder. Am. J. Psychiatry 1985; 142: 163-170.
282.
Ross, S.B., Renyi, A.L.: Inhibition of the uptake of tritiated
catecholamines by antidepressant and related agents. Eur. J. Pharmacol. 1967; 2:
181-186.
283. Rutter, J.J., Auerbach, S.B.: Acute uptake inhibition increases extracellular serotonin in the rat forebrain. J. Pharm. Exp. Ther. 1993; 265 (3): 1319-1324.
284.
Rutter, J.J., Gundlah, C., Auerbach, S.B.: Increase in
extracellular serotonin produced by uptake inhibitors is enhanced after chronic
treatment with fluoxetine. Neurosci. Lett. 1994; 171: 183-186.
285.
Rybakowski, J.K., Lehmann, W.: Decreased activity of erythrocyte membrane
ATPases in depression and schizophrenia. Neuropsychobiol. 1994; 30: 11-14.
286.
Sabelli, H.C., Mosnaim, A.D.: Phenylethylamine hypothesis of affective
behavior. Am. J. Psychiatry 1974; 131 (6): 695-699.
287.
Sabelli, H.C., Borison, R.L., Diamond, B.I., Havdala, H.S.,
Narasimhachari, N.: Phenylethylamine and brain function. Biochem. Pharmacol.
1978; 27 (13): 1707-1711.
288.
Sabelli, H.C., Fawcett, J., Gusovsky, F., Javaid, J., Edwards, J.,
Jeffriess, H.: Urinary phenyl acetate: a diagnostic test for depression? Science
1983; 220 (4602): 1187-1188.
289.
Saito, H., Matsumoto, M.,
Togashi, H., Yoshioka, M.: Functional interaction between serotonin and other
neuronal systems: focus on in vivo microdialysis studies. Jpn. J. Pharmacol.
1996; 70 (3): 203-225.
290.
Salem, N.Jr., Niebylski,
C.D.: The nervous system has an absolute molecular species requirement for
proper function. Mol. Membr. Biol. 1995; 12: 131-134.
291.
Sanders-Bush, E., Conn, J., Sulser, F.: The
serotonin/norepinephrine-linked beta-adrenoceptor system and the mode of action
of antidepressants. Psychopharmacol. Bull. 1985; 21 (3): 373-378.
292.
Sandler, M., Bonham Carter, S., Cuthbert, M.F., Pare, C.M.B.: Is there an
increase in monoamine-oxidase activity in depressive illness? Lancet 1975; I
(7915): 1045-1048.
293.
Sarrias, M.J., Artigas, F., Martínez, E., Gelpí, E., Alvarez, E.,
Udina, C., Casas, M.: Decreased plasma serotonin in melancholic patients: a
study with clomipramine. Biol. Psychiatry 1987; 22: 1429-1438.
294.
Segal, D.S., Kuczenski, R., Mandell, A.J.: Theoretical implications of
drug-induced adaptive regulation for a biogenic amine hypothesis of affective
disorder. Biol. Psychiatry 1974; 9 (2): 147-159.
295.
Sengupta, N.,
Datta, S.C., Sengupta, D.: Platelet and erythrocyte membrane lipid and
phospholipid patterns in different types of mental patients. Biochem. Med. 1981;
25: 267-275.
296.
Seth, R., Jennings, A.L., Bindman, J., Phillips, J., Bergmann, K.:
Combination treatment with noradrenalin and serotonin reuptake inhibitors in
resistant depression. Brit. J. Psychiatry 1992; 161: 562-565.
297.
Shinitzky, M.: Membrane fluidity and receptor function. In: M. Kates,
L.A. Manson, eds. Membrane Fluidity. New York, Plenum Publ. Corp., 1984;
585-601.
298.
Shopsin, B., Friedman, E., Gershon, S.: Parachlorphenylalanine reversal
of tranylcypromine effects in depressed patients. Arch. Gen. Psychiatry 1976;
33: 811-819.
299.
Shreeve, S.M., Valliere, J.E.: The a1-adrenoceptor
is inactivated by alterations in membrane phospholipids. Eur. J. Pharmacol. -
Mol. Pharmacol. Sec. 1992; 226: 29-33.
300.
Schildkraut, J.J.: The catecholamine hypothesis of affective disorders: a
review of supporting evidence. Am. J. Psychiatry 1965; 122: 509-522.
301.
Schildkraut, J.J., Kety, S.S.: Biogenic amines and emotion.
Pharmacological studies suggest a relationship between brain biogenic amines and
affective state. Science 1967; 156 (3771): 21-30.
302.
Schleifer, S.J., Keller, S.E., Meyerson, A.T., Raskin, M.J., Davis, K.L.,
Stein, M.: Lymphocyte function in major depressive disorder. Gen. Psychiat.
1984; 41: 484-486.
303.
Schou, M.: Forty years of lithium treatment. Arch. Gen. Psychiatry 1997;
54: 9-13.
304.
Sibley, D.R., Benovic, J.L., Caron, M.G., Lefkowitz, R.J.: Regulation of
transmembrane signaling by receptor phosphorylation. Cell 1987; 48: 913-922.
305.
Siever, L.J., Murphy, D.L., Slater, S., de la Vega, E., Lipper, S: Plasma
prolactin changes following fenfluramine in depressed patients compared to
controls: an evaluation of central serotonergic responsivity in depression. Life
Sci. 1984; 34: 1029-1039.
306.
Siever, L.J., Davis, K.L.: Overview: toward a dysregulation hypothesis of
depression. Am. J. Psychiatry 1985; 142: 1017-1031.
307.
Siever, L.J., Kahn, R.S., Lawlor, B.A., Trestman, R.L., Lawrence, T.L.,
Coccaro, E.F.: II. Critical issues in defining the role of serotonin in
psychiatric disorders. Pharmacol. Rev. 1991; 43 (4): 509-525.
308.
Sikora, J., Krulík, R.,
Beitlová, D., Příhoda, P.: Plasma levels of antidepressants after their
withdrawal. Endocrin. Experimentalis 1990; 24: 221-227.
309.
Snyder, S.H., Peroutka, S.J.: A possible role of serotonin receptors in
antidepressant drug action. Pharmacopsychiat. 1982; 15: 131-134.
310.
Solomon, G.F.: Psychoneuroimmunology: interactions between central
nervous system and immune system. J. Neurosci. Res. 1987; 18: 1-9.
311.
Song, F., Freemantle N., Sheldon, T.A., House, A., Watson, P., Long, A.,
Mason, J.: Selective serotonin reuptake inhibitors: meta-analysis of efficiancy
and acceptability. BMJ 1993; 306: 683-687.
312.
Souček, K.: Profylaxe
periodických psychóz. Čs. Psychiat. 1988; 84 (3): 206-211.
313.
Spina, E., Perucca, E.: Newer and older antidepressants. A comparative
review of drug interactions. CNS Drugs 1994; 2 (6): 479-497.
314.
Spurlock, G., Buckland,
P., O'Donovan, M., McGuffin, P.: Lack of effect of antidepressant drugs on the
levels of mRNAs encoding serotonergic receptors, synthetic enzymes and 5HT
transporter. Neuropharmacol. 1994; 33 (3/4): 433-440.
315.
Stahl, S.M.: Serotonin receptors and the mechanism of action of
antidepressant drugs: postmortem, platelet, and neuroendocrine studies in
depressed patients. In: S.M. Stahl, M. Gastpar, J.M. Keppel Hesselink, J.
Traber, eds. Serotonin IA Receptors in Depression and Anxiety. New York: Raven
Press, 1992; 119-134.
316.
Stahl, S.M.: 5HT1A receptors and pharmacotherapy. Is serotonin
receptor down-regulation linked to the mechanism of action of antidepressant
drugs? Psychopharmacol. Bull. 1994; 30 (1): 39-43.
317.
Starke, K., Göthert, M., Kilbinger, H.: Modulation of neurotransmitter
release by presynaptic autoreceptors. Physiol. Rev. 1989; 69 (3): 864-989.
318.
Sulser, F., Vetulani, J., Mobley, P.L.: Commentary. Mode of action of
antidepressant drugs. Biochem. Pharmacol. 1978; 27: 257-261.
319.
Sulser, F.: Molecular mechanisms in antidepressant action.
Deamplification of noradrenergic signal transfer by antidepressants: a unified
catecholamine-serotonin hypothesis of affective disorders. Psychopharmacol.
Bull. 1983; 19 (3): 300-304.
320.
Sulser, F., Janowsky, A.J., Okada, F., Manier, D.H., Mobley, P.L.:
Regulation of recognition and action function of the norepinephrine (NE)
receptor-coupled adenylate cyclase system in brain: implications for the therapy
of depression. Neuropharmacol. 1983; 22 (3B): 425-431.
321.
Sulser, F., Sanders-Bush, E.: The serotonin-norepinephrine link
hypothesis of affective disorders: receptor-receptor interactions in brain. Adv.
Exp. Med. Biol. 1987; 221: 489-502.
322.
Sulser, F.: New perspectives on the molecular pharmacology of affective
disorders. Eur. Arch. Psychiatr. Neurol. Sci. 1989; 238: 231-239.
323.
Suranyi-Cadotte, B.E., Bodnoff, S.R., Welner, S.A.:
Antidepressants-anxiolytic interactions: involvement of the benzodiazepine-GABA
and serotonin systems. Prog. Neuro-Psychopharmacol. Biol. Psychiat. 1990; 14
(5): 633-654.
324.
Suzdak, P.D., Gianutsos, G.: Differential coupling of GABA-A and GABA-B
receptors to the noradrenergic system. J. Neural Transm. 1995; 62: 77-89.
325.
Svoboda, P.: Úloha GTP-vazebných proteinů v přenosu hormonálního
signálu. Čs. Fyziol. 1994; 43 (1-2): 20-24.
326.
Švestka, J.: Therapy and
prophylaxis of manic-depressive psychosis with lithium carbonate, with respect
to possibility of prediction of the therapeutic result. In: K. Náhunek, ed.
Advances in psychopharmacology and psychopharmacotherapy, Acta Facult. Med.
Univ. Brunensis 1979; 65: 25-102.
327.
Švestka, J., Náhunek,
E., Češková, E.: Použití carbamazepinu v léčbě a profylaxi afektivních
psychóz. Čs. Psychiat. 1988; 84 (3): 145-155.
328.
Švestka, J., Ryšánek,
R., Češková, E.: Sodium valproate in the treatment of endogenous depressions.
Activ. Nerv. Super. 1990; 32 (3): 231-233.
329.
Švestka, J., Češková,
E., Ryšánek, R., Obrovská, V., Kamenická, V.: K postavení fluvoxaminu ve
skupině antidepresiv. Čs. Psychiat. 1992; 88 (5): 209-219.
330.
Švestka, J. a kol.: Psychofarmaka v klinické praxi. GRADA Publ., Praha,
1995. 252 s.
331.
Teicher, M.H., Glod, C.A., Magnus, E., Harper, D., Benson, G., Krueger,
K., McGreenery, C.E.: Circadian rest-activity disturbances in seasonal affective
disorder. Arch. Gen. Psychiatry 1997; 54: 124-130.
332.
Tejedor-Real, P., Mico, J.A., Maldonado, R., Roques, B.P., Gibert-Rahola,
J.: Implication of endogenous opioid system in the learned helplessness model of
depression. Pharmacol. Biochem. Behav. 1995; 52 (1): 145-152.
333.
Thase, M.E., Trivedi, M.H., Rush, A.J.: MAOIs in the contemporary
treatment of depression. Neuropsychopharmacol. 1995; 12 (3): 185-217.
334.
Trimble, M.R.: Biological Psychiatry. 2nd ed. Chichester, New York,
Brisbane, Toronto, Singapore, J. Wiley & Sons, 1996. 460 s.
335.
Trullas, R., Faiman, C.P., Viu, E.P., Skolnick, P.: Antidepressant
properties of functional antagonists at the NMDA receptor complex. J. Neurochem.
1993; 61 [Suppl]: S50.
336.
Valchář, M.: Jak dál ve vývoji antidepresiv? Čs. Psychiat. 1991; 87
(2): 101-110.
337.
Van den Hoofdakker, R.H.: Chronobiological theories of nonseasonal
affective disorders and their implications for treatment. J. Biol. Rhythms 1994;
9 (2): 157-183.
338.
van Praag, H.M.: In search of the mode of action of antidepressants.
5-HTP/tyrosine mixtures in depression. Neuropharmacol. 1983; 22 (3B): 433-440.
339.
van Praag, H.M.: About the centrality of mood lowering in mood disorders.
Plenary lecture ECNP congress, Monte Carlo, October 1991. Eur.
Neuropsychopharmacol. 1992; 2 (4): 393-404.
340.
Vetulani, J., Sulser, F.: Action of various antidepressant treatments
reduces reactivity of noradrenergic cyclic AMP-generating system in limbic
forebrain. Nature 1975; 257 (5526): 495-496.
341.
Vetulani, J., Stawarz, R.J., Dingell, J.V., Sulser, F.: A possible common
mechanism of action of antidepressant treatment. Naunyn-Schmiedeberg's Arch.
Pharmacol. 1976; 293: 109-114.
342. Vinař, O.: Psychofarmaka II. SPOFA, Praha, 1977. 316 s.
343.
Vinař, O.: Citalopram u
depresí. (Výsledky otevřené multicentrické studie v rámci IV. etapy
klinického hodnocení). Čs. Psychiat. 1993; 89 (6): 340-348.
344.
Vinokur, V.A., Gubachev, Iu.M.: The effect of antidepressants on lipid
metabolism and the clinical course in IHD. Ter. Arkh. 1994; 66 (11): 76-80.
345.
Wachtel, H.: Dysbalance of neuronal second messenger function in the
aetiology of affective disorders: a pathophysiological concept hypothesising
defects beyond first messenger receptors. J. Neural Transm. 1989; 75 (1): 21-29.
346.
Wachtel, H.: The second-messenger dysbalance hypothesis of affective
disorders. Pharmacopsychiat. 1990; 23 (1): 27-32.
347.
Walaas, S.I., Greengard, P.: Protein phosphorylation and neuronal
function. Pharmacol. Rev. 1991; 43 (3): 299-349.
348.
Wander, T.J., Nelson, A., Okazaki, H., Richelson, E.: Antagonism by
antidepressants of serotonin S1 and S2 receptors of normal
human brain in vitro. Eur. J. Pharmacol. 1986; 132: 115-121.
349.
Wardle, J., Armitage, J., Collins, R., Wallendszus, K., Keech, A.,
Lawson, A., for the Oxford Cholesterol Study Group: Randomised placebo
controlled trial of effect on mood of lowering cholesterol concentration. BMJ
1996; 313 (7049): 75-78.
350.
Weiss, J.M., Goodman, P.A., Losito, B.G., Corrigan, S., Charry, J.M.,
Bailey, W.H.: Behavioural depression produced by an uncontrollable stressor:
relationship to norepinephrine, dopamine, and serotonin levels in various
regions of rat brain. Brain Res. Rev. 1981; 3: 167-205.
351.
Wessels,
M.R., Mullikin, D., Lefkowitz, R.J.: Selective alteration in high affinity
agonist binding: a mechanism of beta-adrenergic
receptor desensitization. Mol. Pharmacol. 1979; 16: 10-20.
352.
Wu, J.C., Bunney, E.: The biological basis of an antidepressant response
to sleep deprivation and relapse: review and hypothesis. Am. J. Psychiatry 1990;
147 (1): 14-21.
353.
Young, L.T., Li, P.P., Kish, S.J., Siu, K.P., Warsh, J.J.: Postmortem
cerebral cortex Gs a-subunit
levels are elevated in bipolar affective disorder. Brain Res. 1991; 553:
323-326.
354.
Young, L.T., Li, P.P., Kish, S.J., Siu, K.P., Kamble, A., Hornykiewicz,
O., Warsh, J.J.: Cerebral cortex Gsa
protein levels and forskolin-stimulated cyclic AMP formation are increased in
bipolar affective disorder. J. Neurochem. 1993; 61 (3): 890-898.
355.
Young, S.N., Smith, S.E., Pihl, R.O., Ervin, F.R.: Tryptophan depletion
causes a rapid lowering of mood in normal males. Psychopharmacol. 1985; 87:
173-177.
356.
Zvolský, P.: Rozvoj genetiky v psychiatrii. Avicenum, Zdravotnické
nakl., Praha, 1990. 212 s.